四环医药(00460.HK)9月26日耗资222万港元回购150万股
Ge Long Hui·2025-09-26 11:13

Group 1 - Company announced a share buyback of 1.5 million shares at a cost of HKD 2.22 million on September 26 [1] - The company’s self-developed GLP-1R/GCGR dual-target innovative drug P052 injection has received IND approval [1]